Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-3.6
¥100 million (decrease in net sales from the same period of the previous year)Wording
Conditional
How definitive the wording is.Contents of this document
Financial Results PresentationFiscal year ending July 20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales11,141 Millions of yen-3.1%
Operating profit311 Millions of yen-31.7%
Ordinary income318 Millions of yen-29.8%
Net income223 Millions of yen-37.7%
Gross Profit Margin36.6%
Operating profit margin2.8%
Selling, general and administrative expenses3,766 Millions of yen
Full-year earnings forecast
Fiscal Period CoveredFiscal year ending July 2027
Net Sales
11,363 Millions of yen
Operating profit
437 Millions of yen
Ordinary income
428 Millions of yen
Net income
279 Millions of yen
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Exceeded the earnings forecastNew initiatives
- Review and reorganization of unprofitable businesses
- Withdrawal from the Nagoya Center, scheduled for April 2027
- Acquisition of a pre-owned property in Fukuroi, Shizuoka Prefecture, and operation of the property as a new logistics center equipped with refrigerated-rack warehousing
- Planned launch in early 2027 of the collaborative product “Ginger Ginseng Tea” with アペックス
- Customer acquisition through TV commercials and radio advertising for “Marugoto Sankaku Tea”
- Strengthening of B2B operations overseas through Glocal Depot and SENN
- Strengthening of global B2C operations through Kokoro Care and Amazon
Segment results
- WellnessNet Sales10,189 Millions of yen (YoY -3.6%)Segment profit127 Millions of yen (YoY -52.3%)
- Logistics BusinessNet Sales952 Millions of yen (YoY +2.7%)Segment profit184 Millions of yen (YoY -2.8%)
Medium-term management plan targets
Target fiscal yearFiscal year ending July 2028
Consolidated revenue¥13.1 billion
Operating profit margin6.6%
ROE10.1%
Financial targets
ROE
Target10.1%
Equity ratio
Actual results75.6%
Annual Dividend
Fiscal year ending July 2026
Interim¥15 per share
End of period¥15 per share
Total¥30 per share
Forecast for the fiscal year ending July 2027
Interim¥15 per share
End of period¥15 per share
Total¥30 per share
Payout ratio
Fiscal year ending July 202666.8%
Forecast for the fiscal year ending July 202745.9%
| Item | Details |
|---|---|
| Document type | Financial Results Presentation |
| Fiscal Period Covered | Fiscal year ending July 2026 |
| Net Sales | 11,141 Millions of yen (YoY -3.1%) |
| Operating profit | 311 Millions of yen (YoY -31.7%) |
| Ordinary income | 318 Millions of yen (YoY -29.8%) |
| Net income | 223 Millions of yen (YoY -37.7%) |
| Gross Profit Margin | 36.6% |
| Operating profit margin | 2.8% |
| Selling, general and administrative expenses | 3,766 Millions of yen |
| Full-year earnings forecast | Fiscal Period Covered Fiscal year ending July 2027 / Net Sales 11,363 Millions of yen / Operating profit 437 Millions of yen / Ordinary income 428 Millions of yen / Net income 279 Millions of yen |
| Self-assessment against the plan | Exceeded the earnings forecast |
| Segment results | Segment Wellness / Net Sales 10,189 Millions of yen (YoY -3.6%) / Segment profit 127 Millions of yen (YoY -52.3%), Segment Logistics Business / Net Sales 952 Millions of yen (YoY +2.7%) / Segment profit 184 Millions of yen (YoY -2.8%) |
| Medium-term management plan targets | Target fiscal year Fiscal year ending July 2028 / Consolidated revenue ¥13.1 billion / Operating profit margin 6.6% / ROE 10.1% |
| Financial targets | ROE Target 10.1% / Actual results Not disclosed / Equity ratio Target Not disclosed / Actual results 75.6% |
| Annual Dividend | Fiscal year ending July 2026 Interim ¥15 per share / End of period ¥15 per share / Total ¥30 per share / Forecast for the fiscal year ending July 2027 Interim ¥15 per share / End of period ¥15 per share / Total ¥30 per share |
| Payout ratio | Fiscal year ending July 2026 66.8% / Forecast for the fiscal year ending July 2027 45.9% |
| New initiatives | Review and reorganization of unprofitable businesses, Withdrawal from the Nagoya Center, scheduled for April 2027, Acquisition of a pre-owned property in Fukuroi, Shizuoka Prefecture, and operation of the property as a new logistics center equipped with refrigerated-rack warehousing, Planned launch in early 2027 of the collaborative product “Ginger Ginseng Tea” with アペックス, Customer acquisition through TV commercials and radio advertising for “Marugoto Sankaku Tea”, Strengthening of B2B operations overseas through Glocal Depot and SENN, Strengthening of global B2C operations through Kokoro Care and Amazon |
Items this document does not state (14)
Results for the three months of the current quarterProgress against full-year forecastBreakdown of Factors Affecting the ChangeKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined in the Wellness Business due to slower growth in television shopping, contraction of the catalog mail-order market, and intensifying competition among e-commerce marketplaces. On the profit side, higher costs including raw material and delivery expenses, upfront investment in overseas sales, and higher tariffs and product shipping costs resulting from high crude oil prices and U.S. policy reduced profit. Impairment losses were also recorded on shares in overseas subsidiaries and goodwill related to the overseas business due to weak overseas sales.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.